This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
n17http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n4http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F10%3A00051558%21RIV12-MSM-14110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F10%3A00051558%21RIV12-MSM-14110___
rdf:type
skos:Concept n13:Vysledek
dcterms:description
Dasatinib is effective second line treatment for patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from the real clinical practice of 6 hematological centers in the Czech Republic. Dose 100 mg daily and 70 mg twice daily was administered to patients with chronic phase (CP) and advanced phases (AP) CML. In chronic phase (n=46), complete hematological reponse (CHR) was achieved in 97%, major cytogenetic reponse (MCgR) in 77% and complete cytogenetic response (CCgR) in 67%. Major molecular reponse (MMR) was achieved in 19/31 patients in median of 10 months. In advanced phase (n=25), CHR was attained in 77%, MCgR in 39%, CCgR in 33% and MMR in 2/18 patients. Eleven different baseline mutations were followed up in 15 patients. Dasatinib eliminated mutations in most of the patients, but 3 patients acquired a new one. Dasatinib is effective second line treatment for patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from the real clinical practice of 6 hematological centers in the Czech Republic. Dose 100 mg daily and 70 mg twice daily was administered to patients with chronic phase (CP) and advanced phases (AP) CML. In chronic phase (n=46), complete hematological reponse (CHR) was achieved in 97%, major cytogenetic reponse (MCgR) in 77% and complete cytogenetic response (CCgR) in 67%. Major molecular reponse (MMR) was achieved in 19/31 patients in median of 10 months. In advanced phase (n=25), CHR was attained in 77%, MCgR in 39%, CCgR in 33% and MMR in 2/18 patients. Eleven different baseline mutations were followed up in 15 patients. Dasatinib eliminated mutations in most of the patients, but 3 patients acquired a new one.
dcterms:title
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
skos:prefLabel
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
skos:notation
RIV/00216224:14110/10:00051558!RIV12-MSM-14110___
n3:aktivita
n9:V n9:Z n9:I
n3:aktivity
I, V, Z(MSM6198959205), Z(MZ0UHKT2005)
n3:cisloPeriodika
4
n3:dodaniDat
n12:2012
n3:domaciTvurceVysledku
n10:8478325 n10:5283752 n10:4376285 n10:5378605 n10:1459368 n10:1344153
n3:druhVysledku
n19:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n4:predkladatel
n3:idSjednocenehoVysledku
252921
n3:idVysledku
RIV/00216224:14110/10:00051558
n3:jazykVysledku
n16:eng
n3:klicovaSlova
chronic myeloid leukemia; dasatinib; cytogenetic response; mutation
n3:klicoveSlovo
n5:cytogenetic%20response n5:chronic%20myeloid%20leukemia n5:mutation n5:dasatinib
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[6AC75D183466]
n3:nazevZdroje
Neoplasma
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
17
n3:rokUplatneniVysledku
n12:2010
n3:svazekPeriodika
57
n3:tvurceVysledku
Indrak, K. Moravcova, J. Novakova, L. Faber, E. Oltová, Alexandra Brezinova, J. Mayer, Jiří Michalova, K. Žáčková, Daniela Machova-Polakova, K. Markova, M. Cmunt, E. Dvořáková, Dana Klamova, H. Jarošová, Marie Voglova, J. Cetkovský, Petr
n3:wos
000278262000010
n3:zamer
n17:MZ0UHKT2005 n17:MSM6198959205
s:issn
0028-2685
s:numberOfPages
5
n15:doi
10.4149/neo_2010_04_355
n8:organizacniJednotka
14110